|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
TRANSCRIPTION OF PLASMINOGEN ACTIVATOR INHIBITOR, MODULATOR OF
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
|
|
|
|
Menorrhagia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PAI1 RFLP may prove to be valuable in ordering genetic markers in the CF-linkage group and may also be valuable in genetic analysis of plasminogen activation-related diseases, such as certain thromboembolic disorders and cancer.
|
2891140 |
1987 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The PAI1 RFLP may prove to be valuable in ordering genetic markers in the CF-linkage group and may also be valuable in genetic analysis of plasminogen activation-related diseases, such as certain thromboembolic disorders and cancer.
|
2891140 |
1987 |
|
Fibrosarcoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Dexamethasone increases type 1 plasminogen activator inhibitor (PAI-1) activity released from the human fibrosarcoma cell line HT-1080.
|
3118190 |
1987 |
|
Adult Fibrosarcoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Dexamethasone increases type 1 plasminogen activator inhibitor (PAI-1) activity released from the human fibrosarcoma cell line HT-1080.
|
3118190 |
1987 |
|
Cystic Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PAI1 RFLP may prove to be valuable in ordering genetic markers in the CF-linkage group and may also be valuable in genetic analysis of plasminogen activation-related diseases, such as certain thromboembolic disorders and cancer.
|
2891140 |
1987 |
|
Fibrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Constitutive gene expression of four components of plasminogen activating enzyme system, urinary and tissue-type plasminogen activator (u-PA and t-PA), plasminogen activator inhibitor 1 (PAI-1) and PAI-2 in HT-1080 human fibrosarcoma cells, was modulated by the synthetic glucocorticoid dexamethasone (Dex, 10(-7) M).
|
3126194 |
1988 |
|
Adult Fibrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Constitutive gene expression of four components of plasminogen activating enzyme system, urinary and tissue-type plasminogen activator (u-PA and t-PA), plasminogen activator inhibitor 1 (PAI-1) and PAI-2 in HT-1080 human fibrosarcoma cells, was modulated by the synthetic glucocorticoid dexamethasone (Dex, 10(-7) M).
|
3126194 |
1988 |
|
Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By use of an enzyme-linked immunosorbent assay, we have found that phorbol 12-myristate 13-acetate (PMA) causes an approximately 10-fold increase in the level of type-1 plasminogen activator inhibitor (PAI-1) accumulated in conditioned medium of the human rhabdomyosarcoma cell line.
|
3262618 |
1988 |
|
Childhood Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By use of an enzyme-linked immunosorbent assay, we have found that phorbol 12-myristate 13-acetate (PMA) causes an approximately 10-fold increase in the level of type-1 plasminogen activator inhibitor (PAI-1) accumulated in conditioned medium of the human rhabdomyosarcoma cell line.
|
3262618 |
1988 |
|
Adult Rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By use of an enzyme-linked immunosorbent assay, we have found that phorbol 12-myristate 13-acetate (PMA) causes an approximately 10-fold increase in the level of type-1 plasminogen activator inhibitor (PAI-1) accumulated in conditioned medium of the human rhabdomyosarcoma cell line.
|
3262618 |
1988 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Results from these studies provide direct evidence for an enhancing role of uPA in malignant invasion and experimental metastasis and for a modulatory role of PAI-1 in tumor cell-mediated breakdown of extracellular matrices.
|
2129155 |
1990 |
|
Liver neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
In the current work we have analyzed the regulation of vitronectin by transforming growth factor-beta 1 (TGF beta 1) in this hepatoma cell line by Northern hybridization, polypeptide and immunoprecipitation analyses and compared the response to another TGF beta-regulated gene, plasminogen activator inhibitor (PAI-1).
|
1712727 |
1991 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Fourteen human colon adenocarcinomas were examined by in situ hybridization for the presence of mRNA for plasminogen activator inhibitor type 1 (PAI-1).
|
1855221 |
1991 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to these cell-bound components, the glioblastoma cells also secreted two inhibitors that formed complexes with 125I-urokinase; one was PAI-1, and the other was PN-1.
|
1987320 |
1991 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest a role for u-PA and PAI-1 in a relatively early stage of melanoma metastasis.
|
1918136 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These observations establish that invasive human malignant cells in vivo can activate plasminogen through uPA production during the early phases of tumor growth; they also demonstrate that the proteolytic activity of tumor cells can be modulated by the concomitant production of PAI-1.
|
1918364 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A possible role of PAI-1 in protecting the extracellular matrix in the tumor tissue against degradation and a role in tumor-induced angiogenesis are discussed.
|
1855221 |
1991 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To assess the postulated role of plasminogen activation in tumor invasion, we have investigated the cellular sites of synthesis for urokinase-type (uPA) and tissue-type (tPA) plasminogen activators and their inhibitors (PAI-1 and PAI-2) in two human cutaneous neoplasia that differ in their metastatic potential.
|
1918364 |
1991 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the current work we have analyzed the regulation of vitronectin by transforming growth factor-beta 1 (TGF beta 1) in this hepatoma cell line by Northern hybridization, polypeptide and immunoprecipitation analyses and compared the response to another TGF beta-regulated gene, plasminogen activator inhibitor (PAI-1).
|
1712727 |
1991 |
|
Secondary malignant neoplasm of lung
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, u-PA mediated matrix degradation in vitro and production of u-PA and PAI-1 by human melanoma cell lines correlated with their ability to form spontaneous lung metastasis in nude mice.
|
1918136 |
1991 |
|
Glioblastoma Multiforme
|
0.070 |
Biomarker
|
disease |
BEFREE |
In addition to these cell-bound components, the glioblastoma cells also secreted two inhibitors that formed complexes with 125I-urokinase; one was PAI-1, and the other was PN-1.
|
1987320 |
1991 |